Korro Bio (NASDAQ:KRRO) Major Shareholder Anthony Jr. Florence Acquires 207,100 Shares of Stock

Korro Bio, Inc. (NASDAQ:KRRO) major shareholder Anthony Jr. Florence purchased 207,100 shares of the stock in a transaction that occurred on Tuesday, March 10th. The stock was bought at an average price of $11.11 per share, with a total value of $2,300,881.00. Following the completion of the transaction, the insider owned 1,297,893 shares of the company’s stock, valued at $14,419,591.23. The trade was a 18.99% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Korro Bio Price Performance

Shares of KRRO traded up $1.45 during midday trading on Friday, hitting $12.95. The stock had a trading volume of 552,892 shares, compared to its average volume of 237,193. Korro Bio, Inc. has a 1 year low of $5.20 and a 1 year high of $55.89. The firm has a market cap of $121.97 million, a PE ratio of -1.38 and a beta of 2.98. The stock’s 50 day moving average is $10.90 and its 200 day moving average is $20.23.

Korro Bio (NASDAQ:KRRO) last released its quarterly earnings results on Tuesday, March 17th. The company reported ($5.32) EPS for the quarter, missing analysts’ consensus estimates of ($1.93) by ($3.39). The firm had revenue of $1.29 million for the quarter, compared to analysts’ expectations of $0.43 million. Korro Bio had a negative return on equity of 68.87% and a negative net margin of 1,199.53%. As a group, equities research analysts expect that Korro Bio, Inc. will post -9.52 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Geode Capital Management LLC raised its position in Korro Bio by 10.8% during the 2nd quarter. Geode Capital Management LLC now owns 155,387 shares of the company’s stock valued at $1,941,000 after purchasing an additional 15,166 shares in the last quarter. Raymond James Financial Inc. increased its stake in shares of Korro Bio by 357.6% during the second quarter. Raymond James Financial Inc. now owns 83,392 shares of the company’s stock valued at $1,042,000 after buying an additional 65,170 shares during the period. Bank of America Corp DE increased its stake in shares of Korro Bio by 520.0% during the second quarter. Bank of America Corp DE now owns 28,156 shares of the company’s stock valued at $352,000 after buying an additional 23,615 shares during the period. CWM LLC raised its holdings in shares of Korro Bio by 391.4% in the third quarter. CWM LLC now owns 2,693 shares of the company’s stock valued at $129,000 after acquiring an additional 2,145 shares in the last quarter. Finally, Emerald Mutual Fund Advisers Trust bought a new stake in shares of Korro Bio in the third quarter valued at about $2,821,000. 13.18% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on KRRO. JonesTrading downgraded Korro Bio from a “buy” rating to a “hold” rating in a report on Friday, November 14th. Chardan Capital raised Korro Bio from a “neutral” rating to a “buy” rating and set a $15.00 price objective on the stock in a research report on Thursday, January 29th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Korro Bio in a research note on Friday, January 9th. William Blair upgraded Korro Bio from a “market perform” rating to an “outperform” rating in a research report on Tuesday, February 17th. Finally, Wall Street Zen lowered shares of Korro Bio from a “hold” rating to a “sell” rating in a research note on Saturday, December 13th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $44.50.

Key Korro Bio News

Here are the key news stories impacting Korro Bio this week:

• Positive Sentiment: Raymond James upgraded KRRO from “market perform” to “outperform” and set a $23 price target (~74% upside vs. the recent share level), which can attract momentum buyers and institutional interest. Raymond James Upgrade
• Positive Sentiment: Multiple large shareholders and investors (including Enterprise Associates/NEA‑17, Forest Baskett, Scott Sandell and others) disclosed purchases of ~207,100 shares each at about $11.11 (~$2.3M per filing), increasing their stakes — a strong insider/major‑holder vote of confidence that can support the stock. Insider / Major Holder Buys
• Positive Sentiment: Corporate update: Korro nominated KRRO‑121 for potential treatment of hyperammonemia, is advancing a GalNAc candidate for alpha‑1 antitrypsin deficiency (on track for a development candidate nomination in Q2 2026), and completed an oversubscribed $85M private placement — management says cash runway now extends into H2 2028, reducing near‑term financing risk. Corporate Update & Cash Raise
• Neutral Sentiment: Revenue modestly beat expectations ($1.29M vs. ~$0.42M est.), showing some commercial or other revenue pickup, but the dollar amounts are small relative to R&D burn — limited immediate impact on profitability. Earnings Press Release
• Negative Sentiment: Large quarterly loss: KRRO reported a Q4 EPS loss of ($5.32) vs. consensus (~($1.93)), driving very negative margins and return‑on‑equity metrics — a reminder of high execution risk and binary clinical development outcomes that can trigger volatility. Q4 Results & EPS Miss

Korro Bio Company Profile

Korro Bio, Inc is a clinical-stage biotechnology company focused on harnessing advanced protein engineering and synthetic biology to develop novel enzyme therapies and live microbial therapeutics. The company’s proprietary platform integrates directed evolution, high-throughput screening and computational design to optimize biological catalysts for a wide range of applications. By combining machine learning with experimental biology, Korro Bio seeks to accelerate the discovery and development of next-generation treatments for rare genetic disorders and complex metabolic diseases.

The company’s pipeline features both engineered enzyme therapeutics and live biotherapeutics.